Showing posts with label life sciences. Show all posts
Showing posts with label life sciences. Show all posts

Monday, November 30, 2015

Celebrate Cyber Monday with 25% Off IIR and IBC Pharma and Life Sciences Events

Use code CYBER25 for 25% off the current rate TODAY ONLY. For this exclusive savings use code CYBER25 to register today, November 30th for all the below IIR and IBC Life Sciences pharmaceutical and life sciences conferences:

Antibody Engineering & Therapeutics
December 7-10, 2015
San Diego Convention Center
San Diego, CA
Discount code: CYBER25
Download the brochure: http://bit.ly/1MZnpHL

RIM
Regulatory Information Management Summit
December 14-15, 2015
Ritz Cartlon
Washington DC
Discount code: CYBER25
Download the brochure: http://bit.ly/1lU3rYj

FDA/CMS Summit
December 14-15, 2015
Washington DC
Discount code: CYBER25
View the agenda: http://bit.ly/1lpMvs8

Drug Delivery Partnerships
January 20-22, 2015
PGA National Resort & Spa
Palm Beach Gardens, FL
Discount code: CYBER25
Download the brochure: http://bit.ly/1QPkxU0

Asia TIDES
February 24-26, 2016
Westin Miyako Kyoto
Kyoto, Japan
Discount code: CYBER25
Download the brochure: http://bit.ly/1lU53S2

ePharma
February 29-March 2, 2016
Sheraton Times Square
New York, NY
Discount code: CYBER25
Download the brochure: http://bit.ly/1YD9hLV

BioProcess International Conference & Exposition West
March 14-17, 2016
Oakland Marriott City Center
Oakland, CA
Discount code: CYBER25
View the preliminary agenda: http://bit.ly/1OzE7A6

TIDES
May 9-12, 2016
Long Beach Convention Center and Entertainment Center
Long Beach, CA
Discount code: CYBER25
Download the brochure: http://bit.ly/1OqjtEp

We hope to see you at our 2015-16 events!

*All registrations are subject to approval. Discounts cannot be retroactively applied*

Cheers,
The IIR and IBC Life Sciences Teams






Share this article with your social network, just click below to share now!


Thursday, October 8, 2015

Look Who's Attending | Last Chance to Save up to $400

Last Chance to Save up to $400 is This Friday, October 9th
Register Today
Be Sure to use code: D15172BLOG

  

Connect with hundreds of your colleagues this December in San Diego at the largest and most trusted Antibody Engineering & Therapeutics event to discover, engineer and develop novel and next generation antibody modalities across diverse disease indications. Included with your 4-day registration fee this year is a new 2-day Antibody-Drug Conjugate track that will showcase the latest progress and clinical updates from the most exciting ADC programs in development.

Secure your seat today to attend this year's meeting and access:
• 100+ speaker presentations covering critical scientific and development updates that can accelerate your antibody research, discovery efforts and clinical programs - download the agenda. 
• 50+ exhibitors to keep you on the pulse of evolving technologies
• 100+ scientific posters to give you first-hand updates on unpublished, peer-submitted research projects
• 700+ global antibody researchers for you to connect with onsite to forge successful scientific and business partnerships

A sample of the attending companies:
• Abbvie
• Albert Einstein College of Medicine
• Amgen
• Bayer Healthcare
• Biogen
• Boehringer Ingelheim
• Boston College
• Boston University
• Bramhill Biological Consulting
• Bristol Myers Squibb
• Celgene Corporation
• Covagen AG
• Daiichi Sankyo
• Dana Farber Cancer Institute
• Dartmouth College
• David Geffen School of Medicine at UCLA
• Development Center for Biotechnology
• Eli Lilly & Company
• EnGen Bio
• Esbatech A Novartis Company
• Genentech
• Genesun Biopharmaceutical      
• Genmab BV
• Genomics Inst of Novartis Research
• Genzyme Corporation
• Georgetown University
• GlaxoSmithKline
• Global Biological Standards Institute
• Imaginab
• Immunocore
• ImmunoGen
• Janssen
• Johnson & Johnson
• Jounce Therapeutics
• Kookmin University
• KTH Royal Institute of Technology
• Massachusetts Institute of Technology
• Maxcyte Inc
• MD Anderson Cancer Center
• MedImmune
• Meditope Biosciences
• Memorial Sloan Kettering Cancer Center
• Merck
• Merrimack Pharmaceuticals Inc
• National Cancer Center Hospital East
• National Cancer Institute NIH
• National Institute for Communicable Diseases
• National Research Council Canada
• Novartis
• Novo Nordisk   
• OMT Therapeutics
• Oslo University Hospital, Rikshospi
• Oxford University Kellogg College
• Panorama Research Institute
• Pfizer
• Queen Mary University of London
• Regeneron
• Research Corporation Technologies
• Roche
• Royal Institute of Technology (KTH)
• Sanofi
• Seattle Genetics
• Simon Fraser University
• Stanford University Medical Center
• Stanford University School of Medicine
• Taipei Medical University
• Takeda
• Tel Aviv University
• Teva Pharmaceuticals
• The Rockefeller University
• The Scripps Research Institute
• The University Of Tokyo
• Tokyo University of Pharmacy and Life Sciences• UCL Cancer Institute
• UMass Medical School
• Univ. of Texas MD Anderson Cancer Ct
• University of Cincinnati College of Medicine
• University of Pittsburgh Cancer Institute
• Vaccinex
• Yale School of Medicine and more!

Don't miss out! Join the growing list of attendees at the largest antibody engineering and therapeutics event in the industry! This Friday, October 9th is your last chance to take advantage of the early-bird savings of up to $400. Be sure to use code: D15172BLOG – Register here.

Best,
The Antibody & Protein Therapeutics – From Discovery to Production Team
@ibcusa
#AntibodyEng
http://futurebiopharma.blogspot.com/



Share this article with your social network, just click below to share now!


Monday, September 21, 2015

Closed Systems in Biomanufacturing Offer a Variety of Benefits


I recently attended IBC’s Biopharmaceutical Development and Production week (BDP) and was pleased to find talks focused on single-use technologies, flexible facilities, closed systems and continuous processing. These subjects are sometimes referred to as “biomanufacturing of the future,” because they represent a change in paradigm from traditional biomanufacturing. While we have covered single-use and continuous bioprocessing extensively on Cell Culture Dish in the past, we have not dedicated much time covering the benefits and opportunities associated with closed systems. This blog will attempt to provide a high-level review of some of the topics associated with closed systems and will provide several outside resources for readers who want to explore the topic in more detail.

Traditional Biopharmaceutical Manufacturing

Traditional biopharmaceutical manufacturing has mainly consisted of fed-batch stainless steel bioreactor runs in a fixed facility with an open system. This paradigm, while serving the biopharmaceutical industry well for many years, has faced increasing pressure as single product 20,000L scale manufacturing has begun to lose ground to smaller volume, multi-product manufacturing. This shift has occurred for several reasons, some include:

·         Increases in productivity have reduced the need for very large scale manufacturing vessels and dedicated facilities.
·         Fewer blockbuster drugs with high volumes have reduced the need for large-scale dedicated facilities.
·         Single-use technologies have enabled the implementation of smaller, more flexible manufacturing.
·         Companies have begun to embrace the idea of more flexible, multi-product facilities that can easily be scaled up or down to meet changing product demand.

As a result of the changing landscape, the traditional biomanufacturing paradigm has been challenged by new models including flexible facilities, single-use systems and continuous processes that can create a more flexible and in many cases more cost effective process. Biomanufacturing of the future incorporates technologies like single-use and models like closed systems and continuous processing to move the industry forward.

Closed and Functionally Closed Systems

There have been several definitions of what makes a closed or functionally closed system in biomanufacturing. All the definitions are similar, but I like the definitions used in the BioPharm International article “Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances.” The article provides the following definitions:
  • Closed system: A process system with equipment designed and operated such that the product is not exposed to the room environment. Materials may be introduced to a closed system, but the addition must be done in such a way to avoid exposure of the product to the room environment (e.g., by 0.2 μm filtration).
  • Functionally closed system: A process system that may be routinely opened (e.g., to install a filter or make a connection), but is returned to a closed state through a sanitization or sterilization step prior to process use. It is the owner’s responsibility to define and validate the sanitization or sterilization process required to return an opened system to a functionally closed system
Benefits of a Closed or Functionally Closed System

Reduced Risk of Contamination
One of the biggest and most easily attained benefits of implementing a closed system, whether in research, pilot or large scale, is in reducing the risk of contamination by viruses or other adventitious agents. Open systems naturally provide more opportunities for contamination because the process is open to the room environment and handling by operators. There are also safety concerns associated with breeches of product containment. Operations like fluid transfer present a much higher risk in an open system where splashing and lost media can occur. A closed system, by design, provides physical barriers to reduce the risk of contamination and contain the product.

This is important because contamination can be extremely costly, not only in product loss, but also facility shut downs, cleaning and validation.

Reduced Process Time
The use of a closed system can reduce operating time. A closed system relies on less operator handling and fewer overall steps. Another time saving factor is that many of the closed system components are plug and play meaning that they come pre-assembled, designed for the job they are intended. This reduces the time it takes to set up and launch a manufacturing system significantly.

If single use technologies are employed as part of the closed system, then more time savings can be achieved. Over the course of several talks, the use of single use technologies were reported to save anywhere from a couple of days to a couple of weeks. These times savings were reported in areas including:
  • Reduced cleaning and validation time
  • Reduced set-up time
  • Reduced time to operate or oversee equipment
Examples of Benefits
One example where there is a benefit to time savings and risk reduction is in media preparation. To enable a closed system, instead of mixing and adding media, one might purchase a pre-filled media bag with a connector that is complimentary to a single use bioreactor. This creates a closed portion of the process and saves operator time of mixing media. This method also reduces risk of contamination because the media isn’t exposed to the room environment and there is reduced risk of spilling and loss of media. Aseptic transfer of large volumes of sterile media and solution can be a big challenge.

Another example was provided in a talk at BDP, titled “Processes of the Future: Single Use, Closed and Continuous for Faster, Cheaper and Safer Manufacturing,” given by Sébastien Ribault, Ph.D., Director Biotechnology/Life Science, Head of BioDevelpment Center, EMD Millipore. BDP. In Dr. Ribault’s facility, his team is operating a closed system in one of their manufacturing areas. The group needed to close the cell seeding process, so instead of banking cells in vials, they banked the cells in bags. They then thawed the bags in a water bath and seeded directly in the lab without laminar flow. This saved them time and they reported similar growth and viability to the process using cells banked in vials.

Adopting a Risk Based Approach to Manufacturing Classifications
One hot topic in the discussion around closed systems is the idea of adopting a risk-based approach when it comes to the manufacturing classifications required with closed systems. If a system is closed, or functionally closed, then a barrier already exists between the product and its environment. Therefore, is there really a need for these operations to be conducted in a Classified environment with extensive gowning and airlocks, or would it be more feasible to conduct these operations in a Controlled Non-Classified (CNC) space? The benefits associated with this type of change in classification would provide many manufacturing benefits.

At BDP, Kenneth Green, Ph.D., Head of Manufacturing Science and Technology, Shire, gave an excellent talk titled, “Pushing the Controlled Non-Classified (CNC) Envelope with the Application of Single-Use Systems for Bioprocessing.” In the talk, Dr. Green discussed the debate around whether a closed system or functionally closed system could be proved to regulators, with satisfaction, so that manufacturing could occur in a controlled non-classified environment.

If so, operating in a Controlled Non Classified (CNC) space would open up many more benefits including:
  • Enabling a truly flexible facility – by reducing the classified area requirements you could also reduce the amount of segregation in a facility and increase flexibility. There are many benefits associated with flexible manufacturing, including:
    • Smaller facilities with a simpler design that can be duplicated in multiple locations
    • Multiple products can be manufactured in the same facility or space
    • Less segregation
    • Equipment can be moved around on skids as needed to meet product demand in multiple production lines.
    • Personnel can also move more easily throughout the facility
  • Reduced operating costs include:
    • Energy savings by reducing the environmental monitoring needed and the air handling requirements
    • Removing or reducing gowning requirements reduce cost of both gown materials and provide time savings for the gowning/de-gowning processes.
The idea of employing a risk-based approach in classification requirements is a very interesting topic that could be a blog entirely on its own; however for the purposes of this article, I am only providing a high level overview. There are a number of excellent articles that cover this topic in more detail including:



Challenges to Implementation of a Closed System

Employee Training
While most of these systems are fairly easy to use, there are some major differences between stainless steel systems and single-use. Employees should be trained in maintaining the closed or functionally closed system, proper use of equipment to prevent breakage or tears and employees need to be comfortable using the tubing and connectors.

Breaking New Ground
Completely closed systems represent relatively new technologies. Ensuring all parts of your system are closed may require a good deal of ingenuity and determination particularly when using components from several suppliers. There may not be an off the shelf component that works for you and you may need to work with suppliers to create systems that work for your process.

One example of this ingenuity and determination appeared in Dr. Veena Warikoo’s talk at BDP. Dr. Warikoo, Director, Purification Development, Genzyme, gave a talk titled “Integrated and Fully Continuous Processing of Recombinant Therapeutic Proteins – From Cell Culture Media to Purified Drug Substance.” In the talk she described how Genzyme developed a closed, continuous model system for manufacturing both mAbs and non-mAbs. They had been using a continuous system upstream but needed to also close the downstream process. There wasn’t an off the shelf solution available at the time, so they partnered with GE Healthcare to develop a functionally closed periodic counter-current chromatography continuous process. She showed a picture of the system they used, then stated that GE Healthcare now offers an off the shelf version in their AKTA system.

Demonstrating to Regulators that Systems are Closed and Adopting Risk Based Approach in Classification for Closed Systems
In order to fully gain all of the benefits mentioned above, the industry must work with regulators to demonstrate that CNC manufacturing space is appropriate. BioPhorum Operations Group (BPOG) is currently working to help interpret regulatory guidance and quality expectations and prepare responses that incorporate a risk based approach.

Is a closed system right for your process? – How to navigate a transition
I was able to speak with Erika Hanley-Onken and John Shyu at Corning Life Sciences about their experiences helping customers’ transition to closed systems. They said that they like to conduct a walk through with customers to understand on a technical level the customer’s current system and how that system will transition into a new closed system. They also work with multiple vendors to create a system designed to meet customer needs and goals. Lastly, they train the company on using the new system and they will work with customers to help validate the new system. When asked what customers are most surprised by when deciding to transition they said “how long it takes, it can take weeks to months to develop the system and test it, but we provide a full quality package and we want to ensure that the customer can achieve full and consistent results.”

Goals
First it is important to consider what is the primary goal in moving to a closed system. Some examples below:
  • Designing a new facility and want to incorporate flexible manufacturing principals
  • Quality control concerns and are interested in reducing risk of contamination
  • Process improvements with desire to reduce production time or cost
Design and Implementation of a Closed System
In determining the design and implementation of your closed system it is critical to truly understand your existing process needs, strengths and weaknesses. These factors can be very helpful when working with a vendor or vendors to establish your system. It is also important to understand your current cost of goods and net present value analysis, particularly if cost is a driving factor for change. This will allow you to compare your current system against the proposed system once you have a scale model running.

It is imperative to find a partner that you can work well with. Several talks stressed the keys to a good partnership, and I have included some of them below:
  • It is important for companies to understand their process and share this with supply partners.
  • Choose a supplier you trust and can work with. They have to know what your concerns and goals are so they can build a system that works for you.
  • A supplier should have a quality package and service to help with validating the new system.
Supply partners can be a single vendor who will work to design a process using theirs and complimentary products. A company may also choose a supply partner that has the capability to utilize multiple product vendors to put together a system that is compatible.
This blog was first published on CellCultureDish.com




Share this article with your social network, just click below to share now!


Monday, September 14, 2015

The 4Vs framework and its application in Biopharmaceutical manufacturing

Bioprocessing is an endeavor with some specific challenges associated with it, such as how we might implement single-use technologies or gain regulatory approval for new drugs. It seems to me, however, that it is easy to become so focused on topics such as these that we overlook applying established methods and practices used in a broad array of industries to improve our own. One such framework that could be applied to our sector is an analysis of the 4Vs of volume, variety, variation and visibility. Considering these parameters can help us make decisions about how to best organize biopharmaceutical manufacturing operations.

Volume: The number of doses of a biopharmaceutical to be manufactured varies considerably between drug products. Blockbuster products and products used to manage chronic diseases over long periods of time might be manufactured in large volumes. Due to the specific nature of biopharma drugs the patients that will respond to them can be small and the number of doses required not nearly so many. Orphan drugs for treating relatively rare diseases are a good example of products where the number of doses per year to be manufactured might be very low. Taking this to an extreme, personalized medicines and cell therapies are likely to be required is such small volumes that they are challenging existing industry processing technologies, supply networks and regulatory frameworks in order that they can be successfully commercialized.

Variety: Often linked by an inverse relationship to volume, variety refers to the number of different products an operation must deliver. In the above example of personalized medicine the variety of products to be produced may be very high as the products are in essence customized to the patient receiving them. Less variety tends to imply higher volume production and perhaps less operational complexity. Biopharmaceutical companies often strive to develop platform manufacturing processes capable of delivering a variety of products within their portfolio without adding to this complexity.

Variation: The degree to which demand for the product varies can have a significant impact on operation design. This variation can be more predictable, such as with the seasonal flu vaccines or less predictable, perhaps driven by competitor or regulatory activity. Responding to variations in demand can be a significant challenge for the biopharmaceutical industry where making process changes including process scale-up be a slow process with technical and regulatory challenges. Failure to design operations with sufficient agility to respond to demand fluctuations can result in increased lead times and patients not receiving medicines at the time they are required.

Visibility: Biomanufacturing operations are typically exposed to a high level of internal and external scrutiny due to the regulated nature of the industry. Process visibility is a term often used to describe operations that deliver services in which the customer is typically heavily involved in their design and operation. An example in biologics manufacturing are the use of Contract Manufacturing Organizations (CMOs). Once the decision has been made to outsource production, the management of the relationship between customer and contractor must be given significant attention to ensure successful delivery of drugs to patients and the sponsor must address issues such as relinquishing of some control.

Consideration of the 4Vs can help shape the design of biomanufacturing operations. For instance, high volume-low variety operations are typically more repetitive in nature and may suggest continuous biomanufacturing is an appropriate strategy. Companies requiring a small number of doses of a large number of products will need to design operations that permit a greater level of complexity and more intermittent processes. It is a framework worth reviewing when considering the future design of your companies bioprocessing footprint.




Join me at #BPIconf
Contact me at nick.hutchinson@parker.com

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.



Share this article with your social network, just click below to share now!


Tuesday, September 1, 2015

Top Scientists Address Downstream Processing

Characterization of Host-Cell Proteins Using Mass Spectrometry Enables Effective Purification Optimization

Lin Zang, Senior Scientist, Analytical Development, Biogen describes the mass spectrometry workflow for host cell protein identification that she will be presenting on at the BioProcess International Conference & Exposition, and discusses the implications of HCPs on downstream process development.

Hear more from Lin at 4:00 pm on Wednesday, October 28, 2015 at BPI.

Listen to her interview here: http://bit.ly/1VucXxR



A Novel Approach to Monitor Clearance of Host Cell Proteins Associated with Monoclonal Antibodies 

The big challenge in downstream process development concerning host cell proteins is that the amount of HCPs in the purified product is often so low that it is hard to determine the identity of the HCP. Min Zhu, Senior Scientist, Purification Process Sciences, MedImmune LLC, describes how the approach she will be presenting at the conference overcomes this challenge.

Hear more from Min at 4:30 pm on Wednesday, October 28, 2015 at BPI.

Listen to her interview here: http://bit.ly/1VucXxR



Implementing Multi-Attribute LC/MS Methods for More Informed Process Development 

Matthew Traylor, Analytical Scientist, Process Development, Shire, discusses how he gets a deep characterization a specific protein out of a mixture, using LC/MS software packages that automate the process. He shares how this technology can be used at laboratory, pilot and production scale process development.

Hear more from Matthew at 9:20 am on Tuesday, October 27, 2015 at BPI.

Listen to his interview here: http://bit.ly/1NKYZWY



Continued Process Verification (CPV) Informatics Systems and Validation 

Carly Cox, Senior Process Engineer, Pfizer, describes what a CPV informatics system is and how it’s used in product manufacturing. She’ll be presenting at the BioProcess International Conference on how multiple source systems can pull data on product manufacturing processing and be collected into a CPV informatics system, and some of the important areas to consider for validation and configuration for regulatory reporting and process monitoring.  

Hear more from Carly at 9:20 am on Wednesday, October 28, 2015 at BPI.



Rapid Microbiological Methods for Real-Time Release of Autologous Cell Therapy Products 

Hear about how a risk based approach to autologous cell therapy products used at Vericel. In this podcast, John Duguid, Principal Scientist, Vericel Corporation, describes how rapid microbiological methods are used in product release of autologous cell therapy products, and discusses the areas of contamination risk. Audio Player

Hear more from John at 2:00 pm on Thursday, October 29, 2015 at BPI.

Listen to his interview here: http://bit.ly/1IFdZ0I

If you haven’t already, register for BPI 2015 taking place this fall in Boston. BPI is engineered to be exactly what YOU need it to be. Formal and informal networking experiences connect you to peers, prospects, and customers. Parallel tracks give you the option to dive deep or take a big picture approach to learn about industry trends, challenges, and benchmark against the latest research developments. Big pharma and large, mid-size and emerging biotechs collaborating with solution providers featuring proven and next generation technologies make BPI a one-of-a-kind meeting place.As a valued reader of our blog, you get an exclusive $100 off the current rate when you use code XB15171BLOG. Register here: http://bit.ly/1JA9EQe




Share this article with your social network, just click below to share now!


Wednesday, April 29, 2015

Earn a FREE Pass to the Bioprocess International in Boston, MA – Become a Guest Blogger!

Earn a complimentary all-access pass to Bioprocess International Conference & Exposition by serving as a Guest Blogger at the event. As a Guest Blogger, you’ll have access to the Bioprocess International event’s comprehensive agenda attracting the best insights from around the world, right in Boston, Massachusetts in October.





Conference & Exposition
October 26-29, 2015
Hynes Convention Center, Boston, MA


We are looking for an industry expert with interest in the following topics:

• Drug Product Manufacturing & Fill-Finish Processing
• Cell Culture & Upstream Processing
• Recovery & Purification
• Manufacturing Strategy
• Analytical, Formulation and Quality
• Early Stage Biologics and Companies

...and who would like to learn about the future trends in bioprocessing!

The premise is to provide Bioprocess and Life & Science related articles, whitepapers, and overall original content with a strong focus on a whole bioprocessing industry from product development to biomanufacturing.
What You get is:

• FREE pass to the conference (valued up to $2,399);
• Access to extensive social learning activities;
• Exclusive admission to a networking community in the industry of your interest!

You also have a chance to GAIN exposure through our five health related-blogs with over 2000 unique visitors monthly each and more than 20 healthcare LinkedIn groups.

Learn more about the Bioprocess International Conference & Exposition event by visiting our website.

Interested & want to learn more about this opportunity? Please contact Krista Lentini at klentini@iirusa.com or call 646 895 7316. Feel free to share your short biography, links to your blog or writing samples, along with a few sentences about why we should choose you to become the Guest Blogger for Bioprocess International Conference & Exposition 2015!
 
We hope to have you join us in Boston!

Cheers,
The Bioprocess International Team

#BPIconf
Future of Biopharma Blog http://futurebiopharma.blogspot.com/


Share this article with your social network, just click below to share now!


Tuesday, April 21, 2015

Are You Keeping Up with Your Competition at TIDES?

Over 70 leading and emerging oligonucleotide and peptide companies will be Exhibiting, providing cutting-edge Spotlight Presentations and/or Sponsoring networking sessions at TIDES 2015, coming to San Diego this May. What do they know?

They know:

·         TIDES is the largest gathering of the oligonucleotide and peptide community where networking and business gets done. Over 50% of the attendees are President’s, VPs, C-Level, Directors and Managers that hold the true buying decision power in their hands. Meeting face-to-face with these decision makers will accelerate business, partnerships and sales.
·         Whether in the Exhibit Hall, between sessions or during the scheduled Networking Receptions, you have direct access to hundreds of leading minds and businesses.
TIDES is the leading source of advances in technology, strategies and case studies that span from R&D through Commercialization. Your company needs to be an important part of this community and conversation.

Why let your competition have all the glory?

·         Secure one of the remaining 10 exhibit spaces left >> Request an updated floor plan
·         Sponsor a Spotlight Presentation and prove that your company is a thought-leader in the industry. We have a few select spots remaining in the agenda. Contact me for subject and topic areas.
·         Brand your company through sponsorship of the TIDES Lounge or other branding opportunities.
·         Capitalize on this unique opportunity to highlight your company's expertise to 800+ qualified attendees from 25+ countries.   As our valued event sponsor/exhibitor, your company's brand awareness extends beyond our attendees to our thousands of targeted email subscribers, website visitors and event prospects.   Give me a call or shoot me an email today to discuss how your participation at this year's TIDES meeting will help you achieve your company's targeted growth goals.

Join us in San Diego next month. Register for TIDES today: http://bit.ly/1OBPwgA
Best,
The TIDES Team



Share this article with your social network, just click below to share now!


Friday, October 10, 2014

Celebrate Columbus Day! Register for Pharma and Healthcare Events Thru Monday and Save $300!

Register for any of the following IIR events and receive a $300 discount*


Mention code COLUMBUSLI when registering for each/any of the following:

-  Register here for IIR’s 15th Annual Business of Biosimilars event taking place October 20-22, 2014 in Boston, MA, visit the website for full details.

-  Register here for IIR’s 15th Annual Immunogenicity and Biotherapeutics event taking place October 20-22, 2014 in Boston, MA, visitthe website for full details.

-  Register here for IIR’s 10th Annual Bioassays and Bioanalytical Method Development event taking place October 20-22, 2014 in Boston, MA, visit the websitefor full details.
Have any questions? E-mail Jennifer Pereira.

*This promotion is only valid October 10th-13th 2014. Offer cannot be applied retroactively to confirmed paying registrants and cannot be combined with any other discounts or promotions. All registrants and guests are subject to IIR approval.




Share this article with your social network, just click below to share now!